ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc

Table 3 Correlation between different responses to NACT and clinic pathological factors in 94 breast cancer tissues

Factors	Response to NACT			Univariate analysis		Multivariate analysis
Factors	Poor	Good	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
ADAM10 expression level (pre-NACT)
Low	15	58	0.013*	0.28 (0.10–0.79)	0.016*	0.25 (0.07–0.86)	0.028*
High	10	11
ADAM10 expression level (post-NACT)
Low	21	36	0.266	2.19 (0.64–7.46)	0.211
High	4	15
Age at diagnosis (years)
< 55	19	30	0.009**	4.12 (1.46–11.58)	0.007**	3.85 (0.99–14.92)	0.051
≥ 55	6	39
Menopause
Yes	13	50	0.055	2.43 (0.94–6.26)	0.066
No	12	19
BMI (kg/m²)
> 23	14	43	< 0.001**	0.77 (0.30–1.95)	0.580
≤ 23	26	11
Histological grade
I	3	3	0.059	0.67 (0.25–1.79)	0.420
II	15	58
III	7	8
Tumor size
T1	2	4	0.772	0.89 (0.31–2.55)	0.827
T2	19	57
T3	4	8
Distant metastasis (before NACT)
Yes	2	5	1.000	0.90 (0.16–4.96)	0.902
No	23	64
Regional lymphatic metastasis (after NACT)
Yes	10	32	0.644	0.77 (0.30–1.95)	0.583
No	15	37

ISSN: 1475-2867